CANVAS - CANagliflozin cardioVascular Assessment Study
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
Sponsor: Janssen Research & Development, LLC
Listed as NCT01032629, this PHASE3 trial focuses on Cardiovascular Diseases and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Janssen Research & Development, LLC, it has been updated 12 times since 2009, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Aug 2017 — Mar 2018 [monthly]
Completed PHASE3
-
May 2017 — Aug 2017 [monthly]
Completed PHASE3
-
Apr 2017 — May 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
- The George Institute for Global Health, Australia
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aguascalientes, Mexico , Ahemadabad, India , Ahmedabad, India , Alicante, Spain , Almelo, Netherlands , Almere Stad, Netherlands , Almería, Spain , Ambawadi, India , Amiens, France , Amsterdam, Netherlands and 295 more locations